The Majority of Human Peripheral Blood CD4+CD25highFoxp3+ Regulatory T Cells Bear Functional Skin-Homing Receptors
2006/10/01 by Kazuki Hirahara, Luzheng Liu, Rachael A. Clark +7 · 27 citations
Immunology and Microbiology · #T-cell and B-cell Immunology #Immune Cell Function and Interaction #Immunotherapy and Immune Responses
paper · pdf · doi:10.4049/jimmunol.177.7.4488
Abstract
CD4+CD25+ T regulatory cells (Treg) are thought to be important in the peripheral tolerance. Recent evidence suggests that human peripheral blood CD4+CD25+ T cells are heterogeneous and contain both CD4+CD25(high) T cells with potent regulatory activity and many more CD4+CD25(low/med) nonregulatory T cells. In this study, we found that virtually all peripheral blood CD4+CD25(high)Foxp3+ Treg expressed high levels of the chemokine receptor CCR4. In addition, 80% of Treg expressed cutaneous lymphocyte Ag (CLA) and 73% expressed CCR6. These molecules were functional, as CLA+ Treg showed CD62E ligand activity and demonstrable chemotactic responses to the CCR4 ligands CCL22 and CCL17 and to the CCR6 ligand CCL20. The phenotype and chemotactic response of these Treg were significantly different from those of CD4+CD25(med) nonregulatory T cells. We further demonstrated that blood CLA+ Treg inhibited CD4+CD25- T cell proliferation induced by anti-CD3. Based on homing receptor profile, CLA+ Treg should enter normal skin. We next isolated CD4+CD25(high) T cells directly from normal human skin; these cells suppressed proliferation of skin CD4+CD25- T cells. Therefore, the majority of true circulating Treg express functional skin-homing receptors, and human Treg may regulate local immune responses in normal human skin.
Cited by
- International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors
- Cutaneous Neuroanatomical and Cellular Response to Dupilumab Treatment in Atopic Dermatitis
- Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. [europepmc]
- Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. [europepmc]
- Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. [europepmc]
- Science of composite tissue allotransplantation. [europepmc]
- The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. [europepmc]
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. [europepmc]
- Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. [europepmc]
- Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. [europepmc]
- Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. [europepmc]
- Reduced skin homing by functional Treg in vitiligo. [europepmc]
- CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. [europepmc]
- Phenotypical and functional specialization of FOXP3+ regulatory T cells. [europepmc]
- Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3. [europepmc]
- The role of regulatory T cells in atopic dermatitis. [europepmc]
- The chemokine superfamily revisited. [europepmc]
- Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. [europepmc]
- International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. [europepmc]
- Organ-specific and memory treg cells: specificity, development, function, and maintenance. [europepmc]
- Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells. [europepmc]
- Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. [europepmc]
- RORα-expressing T regulatory cells restrain allergic skin inflammation. [europepmc]
- Human CD8 + HLA-DR + Regulatory T Cells, Similarly to Classical CD4 + Foxp3 + Cells, Suppress Immune Responses via PD-1/PD-L1 Axis. [europepmc]
- Immunology of Acute and Chronic Wound Healing. [europepmc]
- CCR4 as a Therapeutic Target for Cancer Immunotherapy. [europepmc]
- Regulatory T cells in skin regeneration and wound healing. [europepmc]
Related